Johnson & Johnson Prostate Cancer Drug Abiraterone Boosts Survival

September 10, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

NEW YORK (Reuters) - All patients in a study of a Johnson & Johnson drug for advanced prostate cancer will be offered the medicine after an independent monitoring committee found it demonstrated an improvement in patient survival.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase 3

Johnson & Johnson Family of Companies